Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

NCT02810444 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Disease

Interventions

BIOLOGICAL: IgG Next Generation (BT595)

Sponsor

Biotest

Collaborators

[object Object]